Skip to main content

Day: March 1, 2021

Final terms for bond to be opened 4th  March 2021

To Nasdaq Copenhagen A/S                                                               1st March 2021                                                                                                             Announcement no. 27/2021The full prospectus for the Bond consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated February 23th, 2021.Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.comYours sincerely,Jyske Realkredit A/Swww.jyskerealkredit.comPlease observe that the Danish version of this announcement prevails.AttachmentDK0009405698 –...

Continue reading

Endelige vilkår for ny obligation der åbnes den 04. marts 2021

Til Nasdaq Copenhagen A/S                                                                                       1. marts 2021                                                                                                                                                 Meddelelse nr. 27/2021 Jyske Realkredit åbner den 4. marts 2021 en ny særligt dækkende obligation (SDO). Med denne meddelelse følger de endelige vilkår for obligationerne.Det samlede prospekt for obligationerne består af vedlagte endelige vilkår og det tidligere offentliggjorte ”Basisprospekt for udstedelse af Særligt Dækkede Obligationer (SDO), Realkreditobligationer (RO) og obligationer i medfør af § 15 i lov om realkreditlån og realkreditobligationer m.v. (§ 15 Obligationer)”, dateret 23. februar 2021.Jyske Realkredits basisprospekt er tilgængeligt på Jyske Realkredits...

Continue reading

Emerging Markets Report: Not Much Better Than a Buy Back

ORLANDO, Fla., March 01, 2021 (GLOBE NEWSWIRE) — Since our writers and editors are always in search of trend (not fad) stories and potentially market disruptive changes in society, we’re obviously fans of the pet supply, health and wellness space, which has exploded during this COVID year.Apparently, the management of health and wellness company Better Choice Company (OTCQX: BTTR) is as well, having bet on themselves and the Company’s future vis-à-vis a bold buy back announcement of the Company’s shares.The details are important. Let’s take a look at some points that stand out to us, but before we do, please make sure to read the full release for all the details. This is just an excerpt.Here goes:The Company’s Board of Directors has authorized repurchases of up to $2,000,000 in shares.At today’s price that is a significant purchase...

Continue reading

Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update

Receipt of Complete Response Letter from the FDA for Oral Paclitaxel Plus EncequidarKlisyri® (tirbanibulin) received FDA approval and launched commercially on February 18, 2021The New England Journal of Medicine published Phase III trial data on the efficacy and safety of Klisyri®Product sales in 4Q20 grew 54.4% Y/Y to $21.8 million2021 product sales (excluding proprietary products) expected to be in line with 2020Management to host conference call and webcast today at 8:00 a.m. ETBUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2020.Oral...

Continue reading

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in two upcoming virtual investor conferences.On March 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at 10:20 a.m. PT.On March 23, 2021, Hull will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at 8:30 a.m. PT.A live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at http://investors.maravai.com. An archived version of the webcast will be available a few hours following the completion of each event on the Maravai investor relations...

Continue reading

uniQure Announces 2020 Financial Results and Highlights Recent Company Progress

~ Six patient procedures now completed in Phase I/II for Huntington’s disease, including two procedures conducted in February 2021, with full enrollment of first cohort expected mid-2021 ~~ Last patient in HOPE-B pivotal study to complete 52-week follow-up visit before end of the first quarter of 2021, with top-line data to be presented in the second quarter of 2021 ~~ Analysis of the HOPE-B safety event expected to be completed and submitted to the FDA before end of the first quarter of 2021 ~~ Research & Development Day to be held mid-2021 to announce expanded pipeline and platform advancements ~LEXINGTON, Mass. and AMSTERDAM, March 01, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial...

Continue reading

Astec Reports Fourth Quarter 2020 Results

Fourth Quarter 2020 Highlights (all comparisons are made to the prior year fourth quarter):Net Sales decreased 15.6% to $238.9 millionGross Profit Margin of 23.8% increased 1410 bps; Adjusted Gross Profit Margin increased 260 bpsNet Income increased 183.7% to $15.4 million; Adjusted Net Income of $12.8 million increased 56.1% from $8.2 millionDiluted EPS of $0.67 compared to $(0.81); Adjusted EPS of $0.56 increased from $0.36CHATTANOOGA, Tenn., March 01, 2021 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) announced today its financial results for the fourth quarter and full year of 2020.Fourth quarter of 2020 net sales of $238.9 million decreased 15.6% compared to $283.2 million for the fourth quarter of 2019. Domestic sales decreased $29.3 million or 14.0% and international sales decreased $15.0 million or 20.4% due mainly...

Continue reading

Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.“2020 was a breakthrough year for Arvinas and for the patients we aim to serve, as we reported clear signals of efficacy in both of our clinical-stage programs. These data provided further validation that our approach to protein degradation could potentially change the lives of patients with few or no therapeutic options,” said John Houston, Ph.D., Chief Executive Officer at Arvinas. “Despite the unprecedented circumstances of a pandemic, our clinical trials and preclinical research continued to deliver, and we enter...

Continue reading

Superior Group of Companies, Inc. Reports Operating Results for the Fourth Quarter and Year Ended December 31, 2020

Fourth quarter net sales up 34% and Annual net sales up 40%Fourth quarter earnings per share (diluted) increased 295% to $0.79Net Sales and Year-End backlogs, excluding increases from PPE sales are the highest ever recordedAnnual debt reduction of $31.6 millionSEMINOLE, Fla., March 01, 2021 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC), today announced its fourth quarter and year-end operating results for 2020.The Company announced that for the year ended December 31, 2020, net sales increased $150.0 million or 40% percent to $526.7 million compared to $376.7 million in 2019. Pre-tax income was $51.5 million compared to $15.3 million in 2019. Net income for the fiscal year 2020 was $41.0 million, or $2.65 per diluted share, compared to $12.1 million, or $0.79 per diluted share in 2019.Net sales for the fourth...

Continue reading

Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM EasternNEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2020.“The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported positive results from the pivotal ADVANCE-1 trial of AXS-05 in Alzheimer’s disease agitation, initiated the second pivotal trial of AXS-05 in this indication, received two new FDA Breakthrough Therapy designations, and built out our commercialization infrastructure,” said Herriot...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.